Scientists Discover Potential Ozempic Rival That Could Help People Lose Weight With Less Nausea

Wagovi, eat your heart. In a new research study, scientists say that they have discovered a naturally occurring hormone that can usually help people to lose weight during semaglutid (active ingredients in ojempic and wagovovi) and similar drugs related to similar drugs.

A group of researchers in Stanford Medicine conducted this study, Published Nature in the journal last week. With the help of artificial intelligence, the party identified a previously unknown peptide that was found to be safely reduced to the appetite and weight of rats and small pigs without the cause of nausea or other gastrointestinal symptoms. Further studies will be needed to verify the protection and effectiveness of molecules in humans, but the results provide a tantalizing preview of what may be the future of obesity treatment.

Semaglutids and similar drugs have emerged in recent years Revolutionary For the field of obesity drugs. These drugs are also used for Type 2 diabetes, only prove to help people to reduce weight rather than diet and exercise, starting with results 15% to 20% Weight loss in clinical trials. Semaglotid GLP -1 works by duplicating a hormone that helps us control appetite and metabolism, among other functions (some drugs such as Tirzepatide, both GLP -1 and other related hormones).

These drugs such as groundbreaking, they are commonly known as the cause of annoying GI symptoms and can cause more serious complications such as gastrooprace (stomach paralysis). Scientists are also working to find and develop new generation drugs that can provide more weight loss or provide other benefits, such as pills. Stanford Medicine researchers in that vein created a fancy strategy to find their drug candidate.

Many hormones in the body are only active when their previous ones are cleaned by certain enzymes. These predecessors are called the watchmons and the families of the enzymes that are cut to them are called the Dying Conversion. Researchers looked at one of these enzymes, the watchman convertgement 1/3, which is known to help produce GLP -1. They decided to find out if they could find other useful hunger-related hormones produced by the enzyme. In order to speed up the process of this invention, they have created a computer algorithm (nickname peptide predictor) to narrow the list of potential molecules that adapt to their criteria.

This screening has found a primary batch of 373 guarding that can produce about 2,700 different peptides (peptides are often blocked in larger protein building but they may have their own distinctive function). From there, researchers knew them or had 100 suspected testing that could affect the brain hunger drive (including comparison with GLP -1). And in the end, they marked a molecule that seemed especially hopeful, a 12 amino acid-long peptide, known as Peptide or BRP related to brinp2.

Then scientists tested the BRP on lab rats and tiny pigs (minpigs are considered to be similar to people Metabolic) They found that a single dose of BRP reduces the appetite of both animals in the short term, sometimes by 50%. And gross rats are significantly reduced to the BRP significantly compared to the two -week span, most of which are fat.

Further tests have shown that the BRP’s hunger effects do not involve the GLP-1 receptor in the brain at all, and it cannot only experience GI symptoms associated with ozampic-national drugs. Dose -beings also did not feel in their movement, worrying behavior level or water consuming changes, suggest that BRP can be safely tolerated when taken as a drug.

“Recepters characterized by semaglutide are also found in the brain but also in the intestine, pancreas and other tissues. For this reason, the digestive tract of the ozmphic has a huge impact, including slowing down the movement of food and reducing blood sugar levels. “Study Stanford’s Pathology Assistant Professor Katrin Sowenson Study says Statement From the university. “In contrast, BRP seems to work specially in the hypothalamus, which controls hunger and metabolism.”

The team’s searches are of course the primary at the moment. HRP obesity will require a lot of time and research, including the initial successful clinical trials in humans before being seen as the next big thing. However, the team’s discovery is the last one that semaglutide has truly created a change in sea in the treatment of obesity. There are now dozens of experimental drugs in the pipeline that rivals or even threatening to surpass with ozampic/wagovi, Various sources Semaglutide. As part of them, Swivenson and his colleagues have already filed patents in the BRP and he has co-founded a company that he hopes that molecules for clinical use will develop.

No drug comes without side effects, but the future of obesity can be involving much less nausea on any day.